Resources
Did you mean
GlaxoSmithKline Plc. (23 results)
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Glaxo to Double China R&D Staff in Next Few Years
- By Sophie Taylor SHANGHAI (Reuters UK) - GlaxoSmithKline GSK, the world's second-largest drugmaker, plans to double its research and development staff in China to 350 people in the next few years, an executive said on Tuesday. The company currently employs 170 R&D staff in China and...
- News items 2008-07-08
- Glaxo Chief Seeks Guidance From Health Systems
- (Reuters UK) - Pharmaceutical giant GlaxoSmithKline plans to give government healthcare systems a say in deciding which drugs advance in its research pipeline, Chief Executive Andrew Witty told The Wall Street Journal. The effort is part of Witty's drive to help the world's second-largest drug...
- News items 2008-07-06
- Glaxo Makes Like Ponce de Leon With Sirtris Buy
- You can't fault GlaxoSmithKline for temerity. The U.K. drugmaker's unexpectedly large $720 million bid for Sirtris Pharmaceuticals represents a gutsy bet that the Massachusetts biotech really has a handle on a class of drugs that slow aging. Not that anyone at either company is eager to describe their work that...
- Blog posts 2008-04-22
- Glaxo-Regulus Kicks Off an miRNA Land Grab
- GlaxoSmithKline's willingness to bet up to $600 million on a tiny biotech called Regulus Therapeutics kicks off the latest pharma land grab -- this one for treatments that rely on tiny molecules called microRNAs, or miRNAs for short. New drug technologies -- or "modalities," as the industry...
- Blog posts 2008-04-18
- Glaxo Gets an FDA Warning... With Teeth
- Well before Vytorin became a cause célèbre -- which is to say, about a year ago -- GlaxoSmithKline's Avandia was the drug getting slapped around by critics for, in that case, possible heart problems that had possibly been downplayed or ignored. That case, which led to new warnings on the...
- Blog posts 2008-04-12
Additional Resources
- Pharmaceutical firms ordered to pay $114M
- MONTGOMERY, Ala. AP -- A state court jury on Tuesday found two major pharmaceutical companies defrauded Alabama in a long-running Medicaid drug pricing scheme and ordered the firms to pay more than $114 million in damages. The jury found that GlaxoSmithKline should pay the state $80.8 million...
- Articles 2008-07-04
- Adolor Provides Update on Entereg® OBD Program
- FDA Lifts Clinical Hold on OBD IND EXTON, Pa. -- Adolor Corporation (Nasdaq: ADLR) today issued an update on the Entereg[R] alvimopan Program for chronic opioid bowel dysfunction OBD, under development in collaboration with GlaxoSmithKline (NYSE: GSK). The U. S. Food and Drug Administration FDA has...
- Articles 2008-07-03
- High Growth Reported for the World Smoking Cessation Aids Market
- Reportlinker.com announces that a new market research report related to the Personal care industry is available in its catalogue. World Smoking Cessation Aids Market http://www.reportlinker.com/p090576/World-Smoking-Cessation-Aids-Market.html This report analyzes the worldwide markets for Smoking Cessation Aids in US$ Million. The major product segments analyzed are Nicotine Gum,...
- Articles 2008-07-02
- Silence Therapeutics Announces Board Changes
- Appoints Annette Clancy and Jerry Randall as non-executive directors LONDON, July 1 /PRNewswire/ -- Silence Therapeutics plc (London AIM: SLN) ('the Company') today announced changes to its Board of Directors as part of the company's plan for growth. Effective today, Silence has appointed Annette Clancy...
- Articles 2008-07-01
- Glaxo in Pounds 170m drugs sale to South Africa
- Business News IN BRIEF *GlaxoSmithKline, the UK's biggest drugs company, announced yesterday that it has sold off a number of its treatments to the South African pharmaceutical group Aspen Global. The sales of Eltroxin, Lanoxin, Imuran and Zyloric will raise 170m. GSK's chief executive, Andrew Witty, said...
- Articles 2008-07-01
- Cytokinetics Announces Clinical Data Regarding Ispinesib in Combination With Capecitabine
- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today the results of a Phase Ib clinical trial designed toevaluate ispinesib in combination with capecitabine, an oral chemotherapyagent commonly used in the treatment of breast cancer. Ispinesib is anovel, small molecule inhibitor of kinesin spindle protein KSP, a mitotickinesin essential for proper cell...
- Articles 2008-06-30
- GlaxoSmithKline Responds to FDA on CERVARIX® and Plans to Submit Final Study Data for Approval
- LONDON and PHILADELPHIA, June 30 /PRNewswire-FirstCall/ -- GlaxoSmithKline today provided the following update regarding its application to the U.S. Food and Drug Administration FDA for approval of CERVARIXR, its vaccine to prevent cervical cancer. GSK has submitted its response to questions raised by the FDA in...
- Articles 2008-06-30
- Genmab Reaches Milestone in Ofatumumab Collaboration
- Summary: Genmab has Reached a Milestone in its Ofatumumab Collaboration With GlaxoSmithKline COPENHAGEN, June 30 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today it has reached a development milestone for ofatumumab (HuMax-CD20R) under the terms of its collaboration with GlaxoSmithKline GSK. A milestone payment of approximately DKK...
- Articles 2008-06-30
- Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
- Exelixis Generated 10 IND Compounds and Received over $235 Million SOUTH SAN FRANCISCO, Calif., June 27 /PRNewswire-FirstCall/ -- Exelixis, Inc. announced today that the company and GlaxoSmithKline, Inc. will bring their six-year collaboration to a successful conclusion on October 27, 2008, as scheduled. Under...
- Articles 2008-06-27
- Among The Companies Active in the R&D Field of Muscarinic Receptor Agonists & Antagonists Are Glaxosmithkline, Novartis, Astrazeneca, Ucb Pharma and Many Others
- DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/8b3fcc/competitor_analysi) has announced the addition of the "Competitor Analysis: Muscarinic Receptor Agonists & Antagonists" report to their offering. Product description The Competitive Intelligence Report Muscarinic Receptor Agonists & Antagonists as of November 2007 provides a competitor analysis in the development...
- Articles 2008-06-27
- WellPoint to Cover Rotarix® Vaccine
- INDIANAPOLIS, June 27 /PRNewswire/ -- WellPoint, Inc. announced today that, effective immediately, it will cover the rotavirus vaccine, RotarixR, designed to prevent a virus which causes vomiting and diarrhea in infants and children. This decision to cover RotarixR, manufactured by GlaxoSmithKline, is based on formal recommendations...
- Articles 2008-06-27
- CDC Immunization Advisory Committee Recommends Two New Pediatric Vaccines from GlaxoSmithKline
- ATLANTA and PHILADELPHIA, June 26 /PRNewswire-FirstCall/ -- Highlights Include: -- GSK's ROTARIXR [Rotavirus Vaccine, Live, Oral] recommended for routine vaccination of infants to protect against rotavirus gastroenteritis RGE -- ROTARIX, approved by the FDA on April 3, 2008, is the only rotavirus vaccine that offers...
- Articles 2008-06-26
- A Competitor Analysis of the Antihypertensives Market Including Detailed Market Information and Major Companies Active in the Industry
- DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/1d8ee0/competitor_analysi) has announced the addition of the "Competitor Analysis: Antihypertensives" report to their offering. The Competitive Intelligence Report Antihypertensives as of June 2008 provides a competitor analysis in the development pipeline of novel treatments of pulmonary artery hypertension, arterial hypertension, portal hypertension...
- Articles 2008-06-25
- GlaxoSmithKline Seeks Nonprofits that Provide Access to Healthcare for the 12th Annual GlaxoSmithKline IMPACT Awards
- (Qualified Nonprofit Winners to Receive $40,000 Each - Application Deadline is July 10, 2008) PHILADELPHIA, June 25 /PRNewswire/ -- GlaxoSmithKline will honor up to ten community nonprofit organizations that provide "access to healthcare" in the Greater Philadelphia area at the 12th Annual GlaxoSmithKline IMPACT Awards. Applications...
- Articles 2008-06-25
- FDA Approves KINRIX™ - New Combination Vaccine for Children
- - New option could mean fewer shots for 4 to 6 year-olds in the U.S. - PHILADELPHIA, June 24 /PRNewswire-FirstCall/ -- GlaxoSmithKline announced today that the U.S. Food and Drug Administration FDA has approved KINRIXTM [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus...
- Articles 2008-06-24
- << Previous
- page 1 of 1
- Next >>
Content Types
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
